Group 1 - The core viewpoint of the news is that Xinhan New Materials experienced a decline in stock price and significant changes in financing activities on January 14, with a net financing outflow of 42.04 million yuan [1] - On January 14, Xinhan New Materials had a trading volume of 463 million yuan, with a financing buy amount of 48.88 million yuan and a financing repayment of 90.92 million yuan, resulting in a total financing balance of 363 million yuan, which is 4.43% of its market capitalization [1] - The company has a high financing balance, exceeding the 90th percentile level over the past year, indicating a potentially elevated risk in financing activities [1] Group 2 - As of January 9, the number of shareholders of Xinhan New Materials was 30,300, a decrease of 8.71% from the previous period, while the average circulating shares per person increased by 9.54% to 3,623 shares [2] - For the period from January to September 2025, Xinhan New Materials reported a revenue of 330 million yuan, representing a year-on-year growth of 7.99%, and a net profit attributable to shareholders of 51.53 million yuan, up 23.32% year-on-year [2] - The company has distributed a total of 153 million yuan in dividends since its A-share listing, with 113 million yuan distributed in the last three years [3]

Group 1 - The core viewpoint of the news is that Jiangsu Xinhang New Materials Co., Ltd. has shown a positive stock performance, with a 1.09% increase in share price, reaching 50.18 yuan per share, and a total market capitalization of 8.776 billion yuan [1] - The company specializes in the research, production, and sales of aromatic ketone products, with its main business revenue composition being: 42.36% from specialty engineering plastics core materials, 20.64% from cosmetic raw materials, 20.25% from agricultural and pharmaceutical intermediates, and 16.75% from photoinitiators [1] Group 2 - From the perspective of fund holdings, the Yingda Flexible Allocation A fund (001270) has a significant position in Xinhang New Materials, holding 49,800 shares, which accounts for 4.8% of the fund's net value, ranking as the eighth largest holding [2] - The Yingda Flexible Allocation A fund has achieved a year-to-date return of 32.06%, ranking 2913 out of 8085 in its category, and a one-year return of 28.9%, ranking 3053 out of 8085 [2]

Group 1 - The core viewpoint of the news is that Xinhan New Materials has seen a continuous increase in stock price, with a 5.04% cumulative rise over four days, indicating positive market sentiment towards the company [1] - As of December 24, Xinhan New Materials' stock price is 43.38 yuan per share, with a trading volume of 2.19 billion yuan and a turnover rate of 4.64%, leading to a total market capitalization of 7.586 billion yuan [1] - The company, established on July 25, 2008, specializes in the research, production, and sales of aromatic ketone products, with its main business revenue composition being 42.36% from specialty engineering plastics, 20.64% from cosmetic raw materials, 20.25% from agricultural and pharmaceutical intermediates, and 16.75% from photoinitiators [1] Group 2 - From the perspective of major fund holdings, Yinda Fund has a significant position in Xinhan New Materials, with its Yinda Flexible Allocation A fund holding 49,800 shares, accounting for 4.8% of the fund's net value, ranking as the eighth largest holding [2] - The Yinda Flexible Allocation A fund has achieved a year-to-date return of 15.48% and a one-year return of 13.28%, with a total fund size of 1.7126 million [2] - The fund manager, Liu Yubin, has been in charge for 1 year and 244 days, with the best fund return during his tenure being 26.91% and the worst being 9.3% [2]

Group 1 - The core viewpoint of the news is that Xinhan New Materials experienced a decline in stock price and significant changes in financing activities on November 11, with a net financing outflow of 21.71 million yuan [1] - As of November 11, Xinhan New Materials had a total financing and securities lending balance of 308 million yuan, which accounts for 3.79% of its market capitalization, indicating a high level of financing [1] - The company reported a revenue of 330 million yuan for the period from January to September 2025, representing a year-on-year growth of 7.99%, and a net profit attributable to shareholders of 51.53 million yuan, up 23.32% year-on-year [2] Group 2 - Xinhan New Materials has distributed a total of 153 million yuan in dividends since its A-share listing, with 113 million yuan distributed over the past three years [3] - As of September 30, 2025, the number of shareholders in Xinhan New Materials decreased by 3.55% to 29,900, while the average circulating shares per person increased by 3.68% to 3,672 shares [2]

Group 1 - The core viewpoint of the news is that Xinhan New Materials has shown significant trading activity and financial performance, with a notable increase in stock price and financing activities [1][2]. - On November 6, Xinhan New Materials' stock price increased by 3.31%, with a trading volume of 304 million yuan. The financing buy-in amount was 31.47 million yuan, while the net financing buy-in was 5.74 million yuan [1]. - As of November 6, the total financing and securities lending balance for Xinhan New Materials was 316 million yuan, which represents 3.72% of its market capitalization, indicating a high level of financing activity compared to the past year [1]. Group 2 - As of October 31, the number of shareholders for Xinhan New Materials was 31,000, a decrease of 2.52% from the previous period, while the average circulating shares per person increased by 2.58% to 3,542 shares [2]. - For the period from January to September 2025, Xinhan New Materials achieved a revenue of 330 million yuan, reflecting a year-on-year growth of 7.99%, and a net profit attributable to the parent company of 51.53 million yuan, which is a 23.32% increase year-on-year [2]. - Since its A-share listing, Xinhan New Materials has distributed a total of 153 million yuan in dividends, with 113 million yuan distributed over the past three years [3].

1. Report Industry Investment Rating - No information provided in the given content 2. Core View of the Report - In the first three quarters of 2025, the company achieved an operating income of 330 million yuan, a year - on - year increase of 7.99%, and a net profit of 51.53 million yuan, a year - on - year increase of 23.32%. The company is optimistic about the development of the PEEK industry chain, and the production and market expansion of cosmetic raw material HAP are progressing normally. The company's product毛利率 has rebounded due to increased capacity utilization and decreased raw material prices [25][27][30] 3. Summary According to the Directory 3.1 Research Basic Situation - The research object is Xinhan New Materials, belonging to the chemical raw material industry. The reception time was on October 21, 2025, and the listed company's reception staff included the board secretary Li Xiangfei, the financial director Wang Zhongyan, and the securities affairs representative Ge Mingmin [16] 3.2 Detailed Research Institutions - The research institutions include fund management companies such as Baoying Fund, Chuangjin Hexin Fund, and Xinda Australia Asia Fund; investment companies like Dingtian Investment and Ruiyi Investment; securities companies such as Shenwan Hongyuan and CITIC Construction Investment Securities; other institutions including Marco Polo China Assets and Hongyun Private Equity Fund; and banks such as Ping An Bank [17][18] 3.3 Research Institution Proportion - No information provided in the given content 3.4 Main Content Data - **2025 Q1 - Q3 Brief Analysis**: The company achieved an operating income of 330 million yuan, a year - on - year increase of 7.99%, and a net profit of 51.53 million yuan, a year - on - year increase of 23.32%. The comprehensive gross profit margin and sales net profit margin of products gradually improved. The sales of the main products included 40% of DFBP, 18% of photoinitiators, 22% of cosmetic raw materials, and about 20% of medical and agricultural intermediates [25] - **Question and Answer Session**: - **DFBP**: The product price is adjusted periodically according to raw material prices and other factors and is currently at a low level. The production mainly comes from new capacity, with high capacity utilization and gradually repaired gross profit margin [26] - **PEEK**: It has excellent comprehensive performance, and new attempts in high - end manufacturing fields have added new growth momentum. The company is optimistic about the development of the PEEK industry chain [27][28] - **Cosmetic Raw Material HAP**: The production and market expansion are progressing normally, and the sales volume growth is due to the development of new customers and increased penetration. The product price is adjusted periodically [28] - **Three - Workshop of the Fund - Raising Project**: The equipment is being installed and is expected to be completed by December 2025 [29] - **Reasons for Gross Profit Margin Rebound in Q1 - Q3**: The continuous and stable increase in capacity utilization reduces the fixed cost per unit product, and the raw material price has decreased [30]

Financial Performance - In the first three quarters of 2025, the company achieved a revenue of 330 million CNY, representing a year-on-year growth of 7.99% [2] - The net profit for the same period was 51.53 million CNY, showing a year-on-year increase of 23.32% [2] Product Sales Composition - The sales composition of the company's main products includes: - DFBP: 40% - Photoinitiators: 18% - Cosmetic raw materials: 22% - Agricultural and pharmaceutical intermediates: approximately 20% [3] Product Pricing and Capacity - The pricing of DFBP is influenced by raw material costs and is currently at a low level due to these factors; however, production capacity is increasing, leading to gradual recovery in gross margins [4] - The demand for PEEK is growing due to its excellent properties, with applications in aerospace, medical implants, and high-end manufacturing, indicating a positive industry outlook [5] - The production and market expansion of HAP are progressing normally, with sales growth attributed to new customer acquisition and increased penetration [6] Investment Projects - The progress of the fundraising project for the third workshop (HDO) is ongoing, with equipment installation expected to be completed by December 2025 [7] Margin Improvement Factors - The recovery in product gross margins is primarily due to stable increases in capacity utilization, reduced fixed costs per unit, and a decrease in raw material prices during the first three quarters of 2025 [8]

Report Summary 1. Reported Industry Investment Rating No information provided in the document. 2. Core Viewpoints The report mainly presents the results of a research on Xinhan New Materials, covering the company's basic information, research institutions, and answers to investors' questions about the company's operations, including project progress, cash management, product sales, investment purposes, R & D directions, and the impact of trade protection measures [16][23][28]. 3. Summary by Directory 3.1 Research Basic Situation - Research object: Xinhan New Materials [16] - Industry: Chemical raw materials [16] - Reception time: September 12, 2025 [16] - Listed company reception personnel: Chairman and General Manager Yan Liuxin, Financial Controller Wang Zhongyan, Board Secretary Li Xiangfei, Independent Director Huang Hefa [16] 3.2 Detailed Research Institutions - Institutions: Investors who participated in the company's 2025 semi - annual performance briefing online [19] 3.3 Main Content Data - **Project Progress**: The equipment of the third workshop of the 8000 - ton project is being installed and is expected to reach the intended use state and be put into production in December 2025 [23] - **Cash Management**: The company's cash management is mainly used to purchase cash management products with high safety, good liquidity, and a maximum term of no more than twelve months, such as RMB structured deposits and time deposits [24] - **Foreign Exchange Hedging**: The company did not actually carry out specific foreign exchange hedging business during the reporting period and plans to conduct it within the board - authorized limit according to exchange rate fluctuations [26] - **Product Sales**: The sales of the company's main products such as medical and agricultural intermediates, DFBP, and photoinitiators have all increased to varying degrees [27] - **Investment Purpose**: The company invests in Mingxi Equity Investment Fund and Zhejiang Pengfulong Technology to layout fields related to its main business, achieve industrial synergy and capital appreciation, and strengthen its influence in the special engineering plastics field [28] - **R & D Direction**: The company's main R & D direction is focused on the R & D and process improvement of aromatic ketone core products, including special engineering plastic core raw materials and cosmetic raw materials [28] - **Product Situation**: The penetration rate of the company's HAP product as a cosmetic raw material is gradually increasing, and the HDO production line is under construction. The HDO product can be directly used as a cosmetic raw material with moisturizing and bactericidal effects [30] - **Trade Protection Impact**: The company will closely monitor international market trends, actively explore new international markets, develop new products, and expand the domestic market to reduce the impact of export business risks [30] - **Medical and Agricultural Intermediate Business**: The company's medical and agricultural intermediate products have a large variety. After the new workshop of the 8000 - ton project is put into operation, new customers and markets are developed, resulting in rapid growth [30]

Group 1: Company Operations and Developments - The construction of the third workshop for the 8000-ton project is currently underway, with equipment installation in progress and expected to be operational by December 2025 [2] - The company is focusing its cash management on high-security, high-liquidity products, including structured deposits and time deposits, with a maximum term of twelve months [2] - The company has not yet implemented specific foreign exchange hedging activities but is monitoring exchange rate fluctuations closely [3] Group 2: Product Performance and Market Strategy - Sales of key products such as pharmaceutical intermediates, DFBP, and photoinitiators have shown varying degrees of growth [3] - Investments in Mingxi Equity Investment Fund and Zhejiang Pengfulong Technology aim to enhance synergy with the company's main business and strengthen its influence in the specialty engineering plastics sector [3] - The company is concentrating its R&D efforts on core products related to aromatic ketones and process improvements, with specific advancements to be disclosed in the annual report [3] Group 3: Market Challenges and Adaptations - The company is actively exploring new international markets to mitigate risks associated with U.S. tariffs and trade protection measures affecting exports [4] - The pharmaceutical intermediates segment is expected to become a significant growth driver following the new workshop's production capacity expansion [4]

Group 1: Zhongji United - In the first half of 2025, Zhongji United achieved operating revenue of 818 million yuan, a year-on-year increase of 43.52%, and a net profit of 262 million yuan, up 86.61% [1] - The growth in performance is attributed to the rapid development of the wind power industry, with both domestic and international revenues increasing and new orders continuing to rise steadily [1] - The gross profit margin improved to 50.15%, mainly due to an increase in export revenue, changes in the domestic product structure, and a higher proportion of revenue from the US market [1] Group 2: Xinhang New Materials - In the first half of 2025, Xinhang New Materials reported operating revenue of 229 million yuan, a year-on-year increase of 9.66%, and a net profit of 35.29 million yuan, up 20.40% [2] - The sales volume of the main products increased by approximately 30%, with DFBP, HP, and photoinitiators rising by around 25%, and pharmaceutical intermediates increasing by over 50% [2] - The recovery in gross profit margin is attributed to improved capacity utilization and a decrease in fixed cost allocation [2] Group 3: Tianfu Communication - In the first half of 2025, Tianfu Communication achieved operating revenue of 2.456 billion yuan, a year-on-year increase of 57.84%, and a net profit of 899 million yuan, up 37.46% [3] - The growth in active business is primarily due to the increased delivery of high-speed active products, with the company continuously expanding its customer base [3] - The gross profit margin decreased due to changes in product structure, with a higher proportion of revenue coming from active products [3]